Innovair: Main Therapeutic Uses

Innovair is an inhaled medicine authorized for the treatment of two chronic respiratory conditions in adults: asthma and Chronic Obstructive Pulmonary Disease (COPD).

Uses for Asthma

For asthma, Innovair is indicated for regular maintenance treatment when a combination inhaled corticosteroid and long-acting beta2-agonist is deemed appropriate by a healthcare professional. This includes adult patients whose condition is not adequately controlled with an inhaled corticosteroid and a separate as-needed rapid-acting bronchodilator, or those whose asthma is already adequately controlled on a regimen including both an inhaled corticosteroid and a long-acting beta2-agonist.

This medication helps to manage and prevent symptoms such as wheezing, shortness of breath, and coughing associated with asthma, contributing to improved daily symptom control and reduced risk of exacerbations.

Uses for COPD

Innovair is also indicated for the symptomatic treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in adults. The regular use of this combination therapy assists in relaxing the muscles in the airways to help them stay open, making breathing easier. The full scope of therapeutic indications is defined within the approved product information for this medication.

---

Quick Facts: What Innovair Treats
Asthma: Regular maintenance therapy for adult patients whose symptoms are inadequately controlled by other standard treatment steps.
COPD: Symptomatic treatment for adult patients with severe Chronic Obstructive Pulmonary Disease.

---

Regulatory References

1. EMA therapeutic overview

Who Can and Cannot Use Innovair?

Innovair's eligibility is strictly defined by regulatory documents, focusing on age, underlying health conditions, and absolute contraindications. Use is primarily established for Adults (18 years and above) for the maintenance treatment of asthma and symptomatic treatment of severe Chronic Obstructive Pulmonary Disease (COPD).

---

Absolute Restrictions

Population Status	Regulatory Rule
Contraindicated	Patients with known Hypersensitivity to either active substance (beclometasone or formoterol) or any excipient.
Not Recommended	Adolescents (12–17 years), due to lack of established safety and dosing recommendations.
Prohibited	Children (under 12 years), as use is not recommended due to safety concerns.

---

Conditional Eligibility

Use requires special consideration or caution in several patient groups, as noted in official labeling:

• Organ Function: Use in patients with severe hepatic (liver) or renal (kidney) impairment is restricted because no data are available to guide dosing or safety.
• Comorbidities: The medicine must be used with caution in patients with pre-existing conditions such as specific cardiac arrhythmias, thyrotoxicosis, or diabetes mellitus.
• Pregnancy and Lactation: Use should only be considered if the expected benefits outweigh the potential risks, as documented in regulatory guidelines.

Interactions with other medicines and products

Official regulatory documents define specific pharmacological classes that may interact with Innovair (beclometasone dipropionate and formoterol fumarate dihydrate), requiring caution or restriction.

---

Pharmacodynamic and Clearance Interactions

Interacting Product Category	Regulatory Constraint or Outcome
Other Long-Acting beta2-Agonists (LABAs)	Co-administration is restricted due to the documented risk of additive cardiovascular effects and potential overdose.
Strong CYP3A4 Inhibitors	Increases the systemic exposure of the corticosteroid component (beclometasone's active metabolite), potentially leading to systemic corticosteroid effects.
beta-Adrenergic Blocking Agents (Beta-blockers)	May block the bronchodilatory effects of Formoterol and can lead to severe bronchospasm.
MAOIs, TCAs, and QTc-Prolonging Drugs	May potentiate Formoterol's effect on the cardiovascular system, requiring extreme caution.
Diuretics, Xanthine Derivatives, Other Steroids	May potentiate the risk of hypokalaemia (low serum potassium levels) associated with the Formoterol component.

---

Procedural and Population Constraints

• Halogenated Anesthetics: A procedural constraint is documented: Innovair should not be administered for at least 12 hours before the start of anesthesia to mitigate the risk of cardiac arrhythmias.
• Severe Hepatic Impairment: Increased systemic exposure of both active components is expected in patients with severe hepatic impairment, which is a population-specific clearance consideration.

How Innovair Works

Innovair, a combination inhalation product, targets two distinct mechanistic domains to modulate separate signaling cascades in the airways. The drug comprises an inhaled corticosteroid (ICS) and a long-acting beta-agonist (LABA).

---

Regulation of Cellular Signaling and Gene Transcription

The ICS component acts within cellular domains involving glucocorticoid receptor-mediated signaling. Upon binding, it influences feedback regulation within inflammatory pathways by modifying gene transcription. This alters transcription patterns to suppress the expression and production of pro-inflammatory mediators and proteins, resulting in an altered physiological state at the cellular level.

---

Direct Bronchial Smooth Muscle Relaxation

The LABA component targets systems where beta2-adrenergic transmitters dominate. It functions as an agonist by binding to and activating the beta2-adrenergic receptors on airway smooth muscle cells. This action initiates a direct signaling cascade that increases intracellular cAMP concentration. The resulting effect is the relaxation of the smooth muscle tissue, leading to predictable system-level physiological modulation.

Understanding the Inhalation Process

Innovair is typically administered using a pressurized metered-dose inhaler (pMDI). Achieving the intended therapeutic effect depends on the correct synchronization of manual actuation and inhalation.

Preparing the Inhaler

Before using the device for the first time, or if it has not been used for several days, a test spray into the air ensures the valve is functioning correctly. Prior to each application, the cap is removed from the mouthpiece, and the mouthpiece is inspected for any debris or foreign objects.

General Technique

To facilitate the passage of the medication into the airways, the following steps are generally observed:

• Body Posture: Sitting or standing in an upright position helps to expand the lungs.
• Exhalation: Breathing out gently and as deeply as comfortable, away from the mouthpiece, prepares the lungs for the dose.
• Placement: The mouthpiece is placed between the teeth without biting, and the lips are closed firmly around it to create a seal.
• Inhalation and Actuation: A slow, steady breath in through the mouth is started. Simultaneously, the top of the inhaler is pressed down once to release the medication.
• Breath-holding: After inhaling, the device is removed, and the breath is held for several seconds (ideally up to ten) to allow the particles to settle in the lungs. This is followed by breathing out slowly.

Using a Spacer Device

For individuals who find it difficult to coordinate breathing with the manual release of the spray, a compatible spacer device may be used. A spacer provides a chamber where the medication is briefly held, allowing the user to inhale through a valve at their own pace.

Maintenance and Hygiene

To prevent the buildup of residue that could block the spray, the mouthpiece should be cleaned regularly. This is typically done by wiping the outside and inside of the mouthpiece with a dry cloth or tissue. The canister should not be removed from the plastic actuator during routine cleaning, and the device must remain dry.

Post-Inhalation Care

After completing the required number of inhalations, the cap is replaced on the mouthpiece to protect it from dust. Because the formulation may contain a corticosteroid, rinsing the mouth with water or brushing the teeth after use is recommended to maintain oral hygiene.

Research evidence / Overview of Studies for Innovair

---

Evidence for use in Asthma

This section summarizes the research studies, such as clinical trials, that have evaluated what patterns were observed when Innovair (beclometasone dipropionate/formoterol fumarate) was studied for the daily maintenance treatment of asthma, a condition characterized by fluctuating or episodic manifestations.

Research was conducted using study contexts relevant in trials assessing short-term or episodic symptom patterns in populations that were previously studied on different treatments. Findings describe patterns observed in the studies related to several outcomes, including outcomes monitoring physiological strain or stress and patient-reported outcomes describing perceived discomfort. Overall, research highlights changes measured during the study period, and the data show patterns related to Innovair use.

What is still uncertain is the long-term impact on the body's overall functional balance, as many of these controlled studies focused on defined time intervals. Research is also ongoing to clarify the specific patterns observed in studies examining the combination of the two active components and whether the results differ from the use of each component alone.

---

Evidence for use in Chronic Obstructive Pulmonary Disease (COPD)

This section outlines the available evidence from studies specifically investigating the use of Innovair in research contexts involving fluctuating or unstable symptoms for adults with moderate to severe COPD, which is a condition marked by functional limitations.

Clinical trials have monitored the use of Innovair in adults with severe, stable COPD. The research examined outcomes related to physical discomfort and outcomes reflecting daily functioning, and data describe patterns related to physiological outcomes and perceived discomfort compared to using the bronchodilator component on its own. Evidence was monitored related to outcomes describing episodic or acute changes. Comparative evidence is lacking.

---

What is still uncertain about Innovair

One area where research is still needed is the full characterization of patients who have overlapping conditions, such as both asthma and COPD. Research continues to explore outcomes related to physical discomfort in these groups, as comparative evidence is lacking. Certainty remains low regarding the full long-term systemic effects of inhaled corticosteroids. Follow-up durations were limited in key trials, meaning the long-term effects are not fully established. Additionally, research does not determine whether an individual will respond similarly; findings describe group patterns, and more research is always needed to understand the varying symptom burdens.

Common questions about Innovair (FAQ)

---

Q: How quickly should Innovair start working after I begin using it?

According to pharmacokinetics studies, the active component of the inhaled corticosteroid is absorbed relatively quickly. Its maximum concentration in the bloodstream is generally reached within half an hour after use. This timeline provides an indication of when the medicine begins to be distributed throughout the body.

---

Q: How long does the effect of one dose of Innovair usually last?

The Formoterol part of this medicine is officially classified as a Long-Acting Beta2-Agonist (LABA). This means it is designed to provide sustained opening of the airways. This sustained effect aligns with the medicine's classification for regular, scheduled maintenance use.

---

Q: Can older adults use Innovair without special precautions?

Official product information indicates that a dose adjustment is generally not necessary for older adults. The use of Innovair in the geriatric population is typically determined by a prescribing healthcare professional.

---

Q: What is the general difference between a 'controller' and a 'reliever' inhaler?

A combination medicine like Innovair is intended for regular maintenance treatment (sometimes called a controller) to help prevent symptoms over time. Conversely, a reliever is a separate, rapid-acting bronchodilator. This second type is carried by the patient specifically for the immediate relief of sudden or acute symptoms.

---

Q: Does taking Innovair affect dental health or cause dry mouth?

The corticosteroid component of Innovair is associated with a risk of developing oral candidiasis, often referred to as oral thrush. Official instructions specify rinsing the mouth after use to help minimize this risk. Furthermore, dry mouth is noted in regulatory documents as a possible side effect of the long-acting bronchodilator medicine class.

---

Q: Can I use Innovair if I am pregnant or planning to become pregnant?

Regulatory guidelines state that the use of this medicine during pregnancy or breastfeeding should only be considered if the expected benefits to the patient outweigh any potential risks. Official documents caution that the medicine should only be administered following a careful evaluation of these benefits and risks.

---

Q: Can people who have high blood pressure or heart problems use Innovair?

Official regulatory documents advise caution for patients with pre-existing cardiac conditions. Use requires special consideration in individuals with specific heart rhythm disorders or high blood pressure. Caution is advised for these groups due to the potential influence of the medicine on the cardiovascular system.

---

Q: Is Innovair known to interact with herbal supplements or vitamins?

Official regulatory information indicates that there is generally not enough data from clinical trials to confirm the safety of combining this medicine with various herbal remedies or supplements. It is typically recommended that a patient’s prescribing provider is aware of all supplements being used.

---

Q: What is the risk of developing oral thrush from using an inhaler like Innovair?

Oral candidiasis, or oral thrush, is listed as a common side effect in official regulatory documents. This classification indicates that the condition may affect up to 1 in 10 users of the medicine. For this reason, rinsing the mouth immediately after inhalation is a specified action to manage this risk.

---

Q: Why are combination inhalers like Innovair used instead of two separate inhalers?

Innovair is officially classified as a dual therapy preparation, meaning it combines two distinct types of active agents. This approach provides both a preventative and stabilizing effect to the airways through a single inhalation device. Using a fixed-dose combination is a strategy widely adopted in clinical guidelines to simplify the treatment regimen.

---

Q: Does using Innovair affect bone density over time?

Official safety information notes that systemic corticosteroid effects are possible with this class of medicine. These effects, which include decreased bone mineral density, are listed as being more likely to occur with high doses when prescribed for prolonged periods.

---

Q: Does Innovair need to be shaken before use, and why is this important?

For the Pressurized Metered Dose Inhaler (pMDI) type, official administration technique documents generally include the instruction to shake the inhaler before use. This step is specified to help ensure that the medicine is properly mixed for consistent delivery.

---

Q: What steps are generally recommended to minimize the potential for side effects?

Official instructions specify that rinsing the mouth or gargling with water and spitting it out immediately after inhalation is a primary action to minimize local side effects. This procedure helps reduce the risk of oral fungal infections (candidiasis) associated with the corticosteroid component.

---

Q: What is the typical shelf life of an opened Innovair inhaler?

According to the official storage and disposal instructions, the shelf life after the device is removed from its protective foil pouch is typically limited. The inhaler should be discarded either three months after being opened or when the dose counter reaches zero, whichever comes first.

---

Q: Are there different strengths of Innovair, and what is the difference between them?

The fixed-dose combination product is generally available in different strengths. These strengths contain varying amounts of the two active ingredients: the beclometasone (corticosteroid) component and the formoterol component. The specific strength that is used is based on the prescribing healthcare provider’s determination of the individual’s treatment needs.

---

Q: Can I use Innovair if I have another chronic lung condition?

Official regulatory documents list Innovair as a treatment for the regular maintenance of asthma and Chronic Obstructive Pulmonary Disease (COPD) in adults. These are the chronic respiratory conditions for which the medicine's use has been established and researched.

---

Q: Is there a possibility of becoming dependent on Innovair?

Official safety constraints require that treatment must not be stopped abruptly. This is due to the risk of acute adrenal crisis from the corticosteroid component. When discontinuation is being considered, the dose reduction is typically managed gradually.

---

Q: Does Innovair interact with pain relievers like ibuprofen or acetaminophen?

Official drug interaction data for the corticosteroid class indicates that caution may be required if used with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen. These combinations may have the potential for gastrointestinal or other side effects. Official drug interaction data for this class does not specifically note acetaminophen in this context.

---

Q: What should I do if my symptoms seem to worsen after starting Innovair?

Official patient documents advise seeking medical advice if symptoms appear to worsen after starting treatment. Official documents also advise informing the prescribing provider if the separate rapid-acting inhaler (rescue inhaler) is needed more frequently than usual.

---

Q: Is it safe to drink alcohol while using Innovair?

Official regulatory documents note that certain formulations of the medicine contain a small amount of alcohol (ethanol) as an excipient. This is noted as a specific consideration for patients who may be taking other medicines that are known to interact with alcohol.

---

Q: Does Innovair have any known effects on liver or kidney function?

Official documents state that use is restricted in patients with severe hepatic (liver) or renal (kidney) impairment. This is due to the lack of available official data to guide safe dosing or usage for these specific patient groups.

---

Q: How does Innovair affect athletic performance or exercise?

The Formoterol component is a long-acting beta2-agonist, a type of medicine. This class of medicine is sometimes used in the acute prevention of exercise-induced bronchospasm (EIB) when administered on an as-needed basis. This is the context in which this component's effect on exercise is described in official documents.

---

Q: Are there any specific storage requirements for the Innovair inhaler?

According to official storage instructions, the inhaler must be stored at room temperature. It is crucial that the device is protected from both freezing temperatures and excess heat, as well as direct sunlight, to maintain its integrity.

---

Q: Are there any warnings about vision changes while taking Innovair?

Official safety information states that systemic corticosteroid effects are possible, particularly with high doses used over prolonged periods. These systemic effects include glaucoma (increased pressure in the eye) and cataracts (clouding of the lens), which could lead to vision changes.

---

Q: What are the signs that Innovair may not be working effectively for me?

Official patient documents list signs of potential ineffectiveness as symptoms that do not improve or worsen over time. A key sign is also the frequent need to use the separate rapid-acting inhaler (rescue puffs) to manage symptoms.

---

Q: Can I switch from another inhaler to Innovair easily?

Official regulatory notes indicate that when switching a patient from certain other treatments, the total daily dose of the beclometasone component in Innovair may be lower. The prescribing provider determines the appropriate dose adjustment based on the individual patient's treatment needs.

---

Q: Are there any specific laboratory tests required when using Innovair?

The formoterol component may increase the risk of a condition called hypokalaemia (low potassium levels). Also, prolonged high-dose use of the corticosteroid can lead to systemic effects, such as adrenal suppression. Official documents indicate that both of these effects may require monitoring via laboratory tests.

---

Q: Are there any common reasons why a doctor might decide to stop a patient's Innovair treatment?

Official safety constraints mandate that treatment be immediately discontinued if a serious reaction called paradoxical bronchospasm occurs. For other non-emergency reasons where discontinuation is being considered, the dose must be gradually reduced (tapered) rather than stopped suddenly.

---

Q: How is Innovair generally described in official medical documents?

Official regulatory documents describe Innovair as a medicine for the regular maintenance therapy of asthma and COPD. This means it is typically used on a scheduled basis, often in combination with a separate rapid-acting bronchodilator for managing sudden symptoms.

---

Q: What are the known limitations of using Innovair, according to clinical data?

Official research summaries indicate two key limitations in the clinical data. The full characterization of long-term systemic effects for the medicine is not fully established. Additionally, the data describe patterns found across groups of patients rather than predicting how an individual patient will respond.

---

Q: Is there an official patient information leaflet for Innovair that I can read?

Yes, as part of the official regulatory process, authorities publish documents such as a Patient Information Leaflet (PIL) or a Package Leaflet. These documents accompany the medicine and provide users with detailed, official information on its use, side effects, and storage.

Innovair (budesonide/formoterol) should be stored at room temperature, typically between 68^circF to 77^circF (20^circC to 25^circC). It is crucial to protect the inhaler from excess heat, direct sunlight, and freezing temperatures. Exposure to high heat, especially temperatures above 120^circF (49^circC), can cause the pressurized canister to burst. Do not store the device in damp areas, such as a bathroom, and keep it out of the reach of children.

Disposal of Innovair

The pressurized canister must be disposed of safely, as it can contain residual propellant gas, which is a potent greenhouse gas. Never puncture the canister, burn it, or throw it into general household trash or recycling bins. To ensure proper disposal, return your used, expired, or unwanted inhaler to a pharmacy take-back program or a community collection event designed for hazardous or pharmaceutical waste. The inhaler should be discarded either three months after it is removed from the foil pouch or when the dose counter reaches zero, whichever comes first.